Josh Riggs - 17 Jan 2023 Form 4 Insider Report for Oncocyte Corp (OCX)

Role
Interim CEO
Signature
/s/ Josh Riggs
Issuer symbol
OCX
Transactions as of
17 Jan 2023
Net transactions value
$0
Form type
4
Filing time
19 Jan 2023, 16:18:27 UTC
Previous filing
09 Dec 2022
Next filing
28 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCX Option to Purchase Common Stock Award $0 +257,485 $0.000000 257,485 17 Jan 2023 Common Stock 257,485 $0.4629 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options will become exercisable in three equal installments on each of January 17, 2024, January 17, 2025 and January 17, 2026, subject to continuous service through the applicable vesting date.